Clinical Trials Browser

Interventional × Has results × darolutamide × Clear all

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT04736199 2026-02-27

ARANOTE

Phase 3 Completed

669 enrolled 16 charts

Prostatic Neoplasms

NCT02799602 2025-12-04

ARASENS

Phase 3 Completed

1,306 enrolled 25 charts 2 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT04737109 2023-11-13

ADDItion

Phase 1/2 Terminated

6 enrolled 9 charts

Prostatic Neoplasms

NCT04157088 2023-08-04

DaroAcT

Phase 2 Terminated

30 enrolled 25 charts

Prostatic Neoplasms, Castration-Resistant

NCT04237584 2022-10-07

ESCALATE

Phase 3 Terminated

23 enrolled 11 charts

Metastatic Castration-resistant Prostate Cancer

NCT02200614 2022-06-28

ARAMIS

Phase 3 Completed

1,509 enrolled 13 charts 1 FDA

Prostate Cancer Non-Metastatic

NCT03004534 2020-04-03

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Phase EARLY_PHASE1 Completed

36 enrolled 10 charts

Breast Neoplasms

NCT01317641 2017-03-29

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Phase 1/2 Completed

136 enrolled 28 charts

Prostatic Neoplasms

NCT01429064 2017-02-20

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Phase 2 Completed

76 enrolled 9 charts

Prostatic Neoplasms